Comparative Pharmacology
Head-to-head clinical analysis: ALOCRIL versus OLOPATADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOCRIL versus OLOPATADINE HYDROCHLORIDE.
ALOCRIL vs OLOPATADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from conjunctival mast cells. Also inhibits eosinophil chemotaxis and activation.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
2 drops in each eye four times daily; ophthalmic route.
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
None Documented
None Documented
8.6 hours (terminal elimination half-life in healthy adults; may be prolonged in renal impairment, e.g., up to 18 hours in patients with severe renal dysfunction).
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Renal (primarily unchanged drug; approximately 50-60% excreted unchanged in urine within 48 hours). Biliary/fecal elimination accounts for <10%.
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Category C
Category A/B
Mast Cell Stabilizer
Antihistamine / Mast Cell Stabilizer